Transforming Pharma with Key Trends and Technologies at AUTOMA+ 2024

The Pharmaceutical Automation and Digitalisation Congress (AUTOMA+) 2024 brought together over 290 professionals from leading pharmaceutical companies such as Roche, Johnson&Johnson, Moderna, Pfizer, Novartis, Takeda and other key players.

Neuralink Secures Approval for Clinical Trial of its Implant

Elon Musk’s Neuralink announced on Wednesday that it has received approval to initiate its first clinical trial in Canada, focusing on a device designed to enable individuals with paralysis to control digital devices using their thoughts. The stud...

Chronic Therapies Drive 10% Growth in Indian Pharma Market

Long-term health management products, specifically chronic therapies, have been driving the growth of the Indian Pharmaceutical Market (IPM) with a 10% increase, in contrast to acute therapies which saw a 2% growth, showing a trend towards prolong...

UK MHRA Approves Sparsentan for IgA Nephropathy Treatment

The MHRA in the UK has given the approval to sparsentan (Filspari) for the treatment of IgAN. Berger's disease, or IgA neuropathy, is a kidney condition caused by the accumulation of immunoglobulin A (IgA) antibodies in the kidneys. Sparsentan...

Respiratory Therapies Set to Drive Pharma Growth in Coming Months

Anti-diabetics and cardiac treatments are the main drivers of the domestic pharmaceutical market, with respiratory treatments projected to be the primary growth drivers in November, December, and January. With air pollution persisting, it is...

Glenmark Becomes First Indian Company to Launch Biosimilar of Liraglutide

Glenmark became the first Indian company to introduce a biosimilar of the anti-diabetic GLP-1 drug Liraglutide in India. Additionally, it has revealed a number of collaborations to introduce new drugs, such as partnerships with Jiangsu Alphamab...

Pharmanovia Secures Exclusive Rights for Innovative Antibody

The exclusive license agreement permits Pharmanovia to launch catumaxomab, a unique trifunctional bi-specific monoclonal antibody, for intraperitoneal treatment of malignant ascites in EpCAM-positive carcinoma patients ineligible for additional...

US Drives 30% Sales and 40% Volume for India Pharma

The United States continues to be a crucial market for the Indian pharmaceutical industry, representing approximately 30% of overall sales and capturing a 40% share of the market in terms of volume. Despite possible risks from changes in duty...

Pharma Blister Packaging Adopts Smart Tech for a Future-Ready Market

There is a noticeable shift towards smart packaging technologies in the pharmaceutical blister packaging market. The trend of incorporating digital functions like tracking products using smartphones and reminding patients to take medication on...

China Advances Pharma Innovation for Greater Drug Accessibility

China is upgrading its pharmaceutical industry to make drugs and healthcare more accessible. This is part of its plan to become more self-reliant through “new quality productive forces” driven by technical innovation and a supportive business...

© 2024 India Pharma Outlook. All Rights Reserved.